Cell and Organ Transplantology. 2025; 13(1):4-12 (e2025131174).
DOI: 10.22494/cot.v13i1.174
Development of a personalized approach concept for the application of regenerative technologies in patients with osteoarthritis and avascular necrosis of the hip and knee joints
Holiuk Ye.¹
, Strafun S.¹
, Ostapenko T.², Maslova T.¹
- ¹State Institute of Traumatology and Orthopedics, National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
- ²State non-commercial enterprise Ukrainian scientific and practice center of endocrine surgery, transplantation of endocrine organs and tissues under Ministry of Health of Ukraine, Kyiv, Ukraine
Abstract
Total joint arthroplasty remains the leading surgical treatment for osteoarthritis (OA) and avascular necrosis of the hip and knee joints. However, the growing demand for these procedures drives the search for alternative treatment strategies aimed at slowing the increasing rates of joint replacement in the future. One such alternative is regenerative medicine, particularly the use of cell-based therapies.
The aim of this study was to develop the principles of a personalized approach to the application of regenerative technologies in patients with osteoarthritis and avascular necrosis of the hip and knee joints.
Materials and methods. A total of 485 patients with osteoarthritis and 182 patients with avascular necrosis of the hip and knee joints aged between 18 and 88 years were examined, including 408 women and 259 men. The following methods were used: general clinical examination, laboratory tests (complete blood count, analysis of microRNAs 21, 182, and 214 by PCR), and imaging techniques (X-ray, ultrasound, and magnetic resonance imaging).
Results. We developed a personalized approach for applying regenerative technologies in patients with osteoarthritis and avascular necrosis of the hip and knee joints, which includes two key components: patient selection and treatment planning. The patient selection process for osteoarthritis involves five stages: assessment of radiographic stage of OA, identification of the predominant OA phenotype, evaluation of the patient’s treatment expectations, laboratory testing to identify contraindications to regenerative therapies, and analysis of the patient’s medical history. Treatment planning includes choosing the appropriate type or combination of biotechnological products, analyzing patient-reported outcomes related to quality of life using various scales, and reviewing imaging results (MRI or ultrasound) to assess intra-articular and periarticular changes.
Conclusions. We propose a concept of a personalized approach to the application of regenerative technologies in the treatment of osteoarthritis and avascular necrosis of the hip and knee joints. This approach emphasizes that treatment choice should consider not only the clinical diagnosis but also individual patient characteristics, expectations, and the selection of the most appropriate biotechnological product for therapeutic intervention.
Key words: regenerative technologies; personalized treatment approach; osteoarthritis; avascular necrosis; hip joint; knee joint
Full text PDF
| 1. Khyts AV. Osteoarthritis: current concept of development. Ukr Med J [Internet]. 2020. Available from: https://www.umj.com.ua | ||||
| 2. Dolgopolov OV, Polishko VP, Yarova ML. State and trends of morbidity and disability due to musculoskeletal diseases in Ukraine for the period 2013–2017. Visn Ortop Travmatol Protezuvannia. 2018;(4):75-80. | ||||
| 3. Arden, N, Blanco FJ, Bruyère O, et al. Atlas of Osteoarthritis. Springer Healthcare Ltd., London, 2014:11-19. https://doi.org/10.1007/978-1-910315-16-3_1 |
||||
| 4. Graham P. Avascular Necrosis and Bone Infarcts of the Knee. Orthop Nurs. 2020 Jan/Feb;39(1):59-61. PMID: 31977744. https://doi.org/10.1097/NOR.0000000000000631 PMid:31977744 |
||||
| 5. Steffen RT, Athanasou NA, Gill HS, Murray DW. Avascular necrosis associated with fracture of the femoral neck after hip resurfacing: histological assessment of femoral bone from retrieval specimens. The Journal of bone and joint surgery. 2010; British volume 92(6):787-793. https://doi.org/10.1302/0301-620X.92B6.23377 PMid:20513874 |
||||
| 6. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2005;34(2):120-123. https://doi.org/10.1111/j.1600-0714.2004.00269.x PMid:15641993 |
||||
| 7. Khan AA, Sándor GK, Dore E, et al. Canadian Taskforce on Osteonecrosis of the Jaw. Bisphosphonate associated osteonecrosis of the jaw. The Journal of rheumatology. 2009;36(3):478-490. https://doi.org/10.3899/jrheum.080759 PMid:19286860 |
||||
| 8. https://blog.rehabselect.net/10-startling-statistics-on-joint-replacement surgery | ||||
| 9. Centeno CJ, Pitts J, Al-Sayegh H, et al. Efficacy and safety of bone marrow concentrate for osteoarthritis of the hip; treatment registry results for 196 patients. J Stem Cell Res Ther 2014; 4:242. 471. https://doi.org/10.4172/2157-7633.1000242 |
||||
| 10. Houdek MT, Wyles CC, Martin JR, Sierra RJ. Stem cell treatment for avascular necrosis of the femoral head: current perspectives. Stem Cells and Cloning: Advances and Applications/ 2014;7:65-70. https://doi.org/10.2147/SCCAA.S36584 PMid:24744611 PMCid:PMC3986287 |
||||
| 11. Gangji V, Toungouz M, Hauzeur JP. Stem cell therapy for osteonecrosis of the femoral head. Expert Opinion on Biological Therapy, 2005;5(4):437-42 https://doi.org/10.1517/14712598.5.4.437 PMid:15934823 |
||||
| 12. https://www.orthopaedicscore.com/ | ||||
| 13. Kellgren J, Lawrence J. Radiological Assessment of Osteo-Arthrosis. Ann Rheum Dis. 1957;16(4):494-502. https://doi.org/10.1136/ard.16.4.494 PMid:13498604 PMCid:PMC1006995 |
||||
| 14. Hinzman J, Kupatz P. Standardenbenen der Sonografie der Bewegungsorgane. 2-nd ed., Thieme Verlag KG, Stuttgart, Germany, 2012:144 p https://doi.org/10.1055/b-002-37765 |
||||
| 15. Kuroda Y, Tanaka T, Miyagawa T, et al. Classification of osteonecrosis of the femoral head: who should have surgery? Akiyama Bone Joint Res 2019;8:451-458. https://doi.org/10.1302/2046-3758.810.BJR-2019-0022.R1 PMid:31728183 PMCid:PMC6825048 |
||||
| 16. Loo SJQ, Wong NK. Advantages and challenges of stem cell therapy for osteoarthritis (Review). Biomedical Reports 2021;67:15р. https://doi.org/10.3892/br.2021.1443 PMid:34155451 PMCid:PMC8212446 |
||||
| 17. Thoene M, Bejer-Olenska E, Wojtkiewicz J. The Current State of Osteoarthritis Treatment Options Using Stem Cells for Regenerative Therapy: A Review. Int. J. Mol. Sci. 2023;24:14 р. https://doi.org/10.3390/ijms24108925 PMid:37240271 PMCid:PMC10219560 |
||||
| 18. Y Chen, Cheng RJ, Wu Y, et al. Int. J. Mol. Sci. Advances in Stem Cell-Based Therapies in the Treatment of Osteoarthritis. 2024;25:394. https://doi.org/10.3390/ijms25010394 PMid:38203565 PMCid:PMC10779279 |
||||
| 19. Xiang XN, Zhu SY, He HC, et al. Mesenchymal stromal cell-based therapy for cartilage regeneration in knee osteoarthritis. Stem Cell Research & Therapy 2022;13:14. https://doi.org/10.1186/s13287-021-02689-9 PMid:35012666 PMCid:PMC8751117 |
||||
| 20. Simunec D, Salari H, Meyer J. Treatment of Grade 3 and 4 Osteoarthritis with Intraoperatively Separated Adipose Tissue-Derived Stromal Vascular Fraction: A Comparative Case Series.. Cells 2020;9:2096. https://doi.org/10.3390/cells9092096 PMid:32937996 PMCid:PMC7565051 |
||||
| 21. Freitag J, Wickham J, Shah K, Tenen A. Real-world Evidence of Mesenchymal Stem Cell Therapy in Knee Osteoarthritis: A Large Prospective Two-Year Case Series. Regen. Med. 2022;17(6):355-373. https://doi.org/10.2217/rme-2022-0002 PMid:35411799 |
||||
| 22. Deveza A, Nelson AE, Loeser RF. Phenotypes of osteoarthritis – current state and future implications. Leticia Clin Exp Rheumatol. 2019 ; 37(Suppl 120): 64-72. | ||||
| 23. Calvet J, Garcıa-Manrique M, Berenguer-Llergo A, et al. Metabolic and inflammatory profiles define phenotypes with clinical relevance in female knee osteoarthritis patients with joint effusion. Rheumatology. 2023;62:3875-3885. https://doi.org/10.1093/rheumatology/kead135 PMid:36944271 PMCid:PMC10691929 |
||||
| 24. Saxer F, Hollinger A, Bjurstrom MF et al. Pain-phenotyping in osteoarthritis: Current concepts, evidence, and considerations towards a comprehensive framework for assessment and treatment. Osteoarthritis and Cartilage Open; 2024. 100433. https://doi.org/10.1016/j.ocarto.2023.100433 PMid:38225987 PMCid:PMC10788802 |
||||
| 25. Roemer FW, Jarraya M, Collins JE, et al. Structural phenotypes of knee osteoarthritis: potential clinical and research relevance. Skeletal Radiology. 2023;52:2021-2030. https://doi.org/10.1007/s00256-022-04191-6 PMid:36161341 PMCid:PMC10509066 |
||||
| 26. Im GI, Moon JY. Emerging Concepts of Endotypes/Phenotypes in Regenerative Medicine for Osteoarthritis. Tissue Eng Regen Med. 2022;19(2):321-324. https://doi.org/10.1007/s13770-021-00397-2 PMid:34674181 PMCid:PMC8971261 |
||||
| 27. Kenihan L, McTier L, Phillips NM. Patients’ expectations and experiences of stem cell therapy for the treatment of knee osteoarthritis. Health Expectations. 2020;23:1300-1309. https://doi.org/10.1111/hex.13113 PMid:32794633 PMCid:PMC7696136 |
||||
| 28. Alderman DD, Alexander RW. Advanced in Regenerative Medicine: High-density Platelet-rich Plasma and Stem Cell Prolotherapy For Musculoskeletal Pain. Practical Pain Management. 2011;11(8): 59-90. | ||||
| 29. Crane D, Everts P. Platelet Rich Plasma (PRP) Matrix Grafts. Pract Pain Manag. 2008;8(1):10 p. | ||||
| 30. Голюк ЄЛ, Поляченко ЮВ, Страфун СС, Гайович ІВ, Пшеничний ТЄ. Концептуальні засади застосування регенеративних технологій при остеоартрозі та асептичному некрозі кульшового та колінного суглобів Вісник ортопедії, травматології та протезування. 2021;3:20-27. https://doi.org/10.37647/0132-2486-2021-110-3-20-27 |
||||
| 31. Ferrari M, Zia S, Valbonesi M, et al. A new technique for hemodilution, preparation of autologous platelet- rich plasma and intraoperative blood salvage in cardiac surgery. Int J Artif Organs. 1987;10(1):47-50. https://doi.org/10.1177/039139888701000111 PMid:3570542 |
||||
| 32. Di Matteo B, Filardo G, Lo Presti M, et al. Chronic anti-platelet therapy: a contraindication for platelet-rich plasma intra-articular injections? European Review for Medical and Pharmacological Sciences. 2014; 18(1): 55-59. | ||||
| 33. Bondariev G., Strafun S., Holiuk Ye., Saulenko K., Darovskyi O., Syvak A. Functional Results Analysis of L-PRP Application for Patients with Meniscus Injures of the Knee Joint. Georgian Medical News, 2020;11(308):14-19. | ||||
| 34. D’Souza RS, Her YF, Hussain N, et al. Evidence-Based Clinical Practice Guidelines on Regenerative Medicine Treatment for Chronic Pain: A Consensus Report from a Multispecialty Working Group. Journal of Pain Research. 2024;17: 2951-3001. https://doi.org/10.2147/JPR.S480559 PMid:39282657 PMCid:PMC11402349 |
||||
Holiuk Ye, Strafun S, Ostapenko T, Maslova T. Development of a personalized approach concept for the application of regenerative technologies in patients with osteoarthritis and avascular necrosis of the hip and knee joints. Cell Organ Transpl. 2025; 13(1):4-12 (e2025131174). doi: https://doi.org/10.22494/cot.v13i1.174

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

